Study design: Randomized control. Objective: To examine the eects of testosterone replacement therapy (TRT) on skeletal muscle 11 weeks after complete SCI. Setting: Athens, Georgia USA. Methods: Soleus (SOL), gastrocnemius (GA), tibialis anterior (TA), vastus lateralis (VL) and triceps brachii (TRI) muscles were taken from twelve young male Charles River rats 11 weeks after complete SCI (T-9 transection, n=8) or sham surgery (n=4). Rats received either TRT (two 5 cm capsules, n=4) or empty capsules (n=8) implanted at surgery. Muscle samples were sectioned and ®bers analyzed qualitatively for myosin ATPase and quantitatively for succinate dehydrogenase (SDH), a-glycerol-phosphate dehydrogenase (GPDH) and actomyosin ATPase (qATPase) activities using standard techniques. Results: SCI decreased average ®ber size (49+4%) in aected muscles and the percentage of slow ®bers in SOL (93+3% to 17+2%). In addition, there was a decrease in SDH and an increase in GPDH and qATPase activities across the four hind-limb muscles of the SCI animals. Fiber size in the TRI was increased (31+2%) by SCI while enzyme activities were not altered. Average ®ber size across the four hind limb muscles was decreased by only 30% in TRT SCI animals and their SOL contained 39+2% slow ®bers. TRT also attenuated changes in enzyme activities. There was no eect of TRT on the TRI relative to SCI.
Introduction
It has been estimated that there are approximately 200 000 patients with spinal cord injury (SCI) in the United States alone, with roughly 10 000 new injuries occurring each year. Additionally, the relative number of new injuries is rising and expected to increase by 20% by 2010, compared to 1994 prevalence. 1 SCI is associated with a decrease in perceived quality of life and an increase in several health-related risk factors. Interventions aimed at reducing some of the health risks associated with SCI have been examined over the past two or so decades. As a result of this search and the changes in care and treatment of patients with SCI, the expected life span of this population has increased to approximately the same as for able-bodied persons. However, many health problems remain for this patient group that may be related to the extensive loss of the mass of aected skeletal muscle after injury.
One possible treatment that has received little attention with respect to SCI and sarcopenia is testosterone replacement therapy (TRT). TRT is used to combat a variety of health problems in the aging male. The decreases in strength, muscle mass, reproductive function and bone density with aging have been linked to lower circulating androgens, speci®cally testosterone. 2 Although the bene®t to risk analysis of TRT for able-bodied individuals is sometimes questioned because of the potential for increased hematopoiesis, liver toxicity and prostatic cancer, 3 the potential of this treatment to aid SCI patients has not been examined.
Previous research has shown that TRT can ameliorate the atrophic response resulting from hindlimb unloading in rats, 4 a model that evokes decreases in plasma testosterone similar to those seen in animals with SCI. EMG activity of involved muscles in hindlimb suspended rats is`normal' after 48 h of unloading while aected skeletal muscles after SCI can be electrically silent. Thus, the lack of`activation and associated events', for example active muscle shortening and subsequently lengthening of associated antagonists, could result in dierent eects of TRT in these two models of muscle atrophy. 5, 6 In light of the aforementioned, the purpose of this study was to evaluate the eects of TRT on rat skeletal muscles after SCI. It was hypothesized that TRT would at the least attenuate atrophy after SCI based on the eects of androgen replacement in other models of sarcopenia. This study will not address the concerns surrounding testosterone therapy in humans. 3 However, it will hopefully serve as an initial step in assessing the ecacy of TRT for reducing several increased health risks after SCI. An increase in aected muscle mass in chronic SCI could increase exercise capacity, and thereby reduce the risk for cardiovascular disease. 7 A therapeutically induced increase in muscle mass could also result in increased insulin sensitivity, venous return and metabolic rate with corresponding potential for more favorable body composition and increased bone density, all would have a positive in¯uence on health.
Methods
The soleus (SOL), gastrocnemius (GA), tibialis anterior (TA), vastus lateralis (VL) and triceps brachii (TRI) muscles were taken from 12 young male Charles River rats (131 days old), 11 weeks after complete SCI (T-9 transection, n=8) or sham surgery (n=4). A complete surgical transection of the spinal cord at T-9 with a foam barrier placed between the severed ends of the cord was performed. Rats received either TRT (two 5 cm testosterone capsules, n=4), or empty capsule implantation (n=8) at the time of surgery, as described previously. 8 Rats were housed singly in hanging wire cages with Purina Rat Chow and water ad libitum. Animals were creded three times per day until bladder function returned after recovery from spinal shock (*2 weeks). There was no recovery of voluntary motor function in the hind-limbs of the rats, although some spinal re¯exes did return after recovery from spinal shock.
Excised muscle tissue was mounted in an embedding medium and subsequently frozen in 2-methyl butane cooled in dry ice. Samples were stored at 7708C until analyzed.
Histochemical analyses
Samples were removed from the freezer and placed in a cryostat microtome at 7208C to warm. Serial sections (6, 10 or 14 mm) were cut and placed onto coverslips for immediate assay by both qualitative and quantitative histochemical procedures. Images of the sections were acquired using a Sony xc 77 CCD camera attached to an Olympus bh-2 microscope linked to a Macintosh Quadra 800 computer. Images were saved and analyzed using NIH image software (written by Wayne Rasband at the US National Institutes of Health, zippy.nimh.nih.gov), as done previously. 9, 10 Sections (10 mm) were assayed qualitatively for myo®brillar adenosine triphosphatase activity using the techniques of Brooke and Kaiser 11 and of Guth and Samaha. 12 Single ®bers were analyzed for type by microdensitometric determination of optical density. The myosin ATPase composition, represented by the optical density, which is based on the pH lability of the ®ber, is directly correlated to myosin heavy chain composition of a given ®ber. 13 Quantitative histochemical determination of succinic dehydrogenase activity (SDH) and a-glycerol phosphate dehydrogenase activity (GPDH) were used as estimates of oxidative and glycolytic energy supply, respectively, essentially as done previously.
9,10 SDH and GPDH activities were determined by the microdensitometric technique described by Blanco et al., 14 and Martin et al, 15 respectively. Images were captured using the same tools as for ®ber typing with the exception that a narrow pass interference ®lter with peak emission of 570 nm was used so as to assess maximal absorption of Nitro-blue tetrazolium-diformazan, the in-vitro reaction end product. Enzyme activities were obtained from the dierence in optical density between samples incubated in the presence and absence of substrate and are expressed as mmol fumerate/l tissue/min and mmol glycerol-3-phosphate/l tissue/min for SDH and GPDH activity, respectively.
The method of Blanco and Sieck (1992) was modi®ed and used for quantitative determination of actomyosin adenosine triphosphatase (qATPase) activity in single ®bers, essentially as done previously for human skeletal muscle. 9 Brie¯y, 6 mm serial sections were incubated in one of six solutions of dierent ATP concentrations (0 ± 3 mM). The use of incubations of dierent concentrations is necessary because, in contrast to the assays for SDH and GPDH, the qATPase reaction is non-substrate limited. The Michaelis-Menten model of enzyme kinetics was used to analyze the data and the reciprocal of the yintercept of the Lineweaver-Burk plot was taken as the maximum velocity of the qATPase in OD/min. Enzyme activity, expressed as mmol Pi per liter of tissue per min, was determined using the Lambert-Beer equation with a molar extinction coecient for leadsul®de of 1450 M 71 cm 71 . Images saved for SDH, GPDH and qATPase assays were matched to those saved for ®ber typing, thus allowing values obtained for individual ®bers in serial sections to be matched and expressed relative to ®ber type and ®ber size. This provides both a qualitative indicator of ®ber properties via their type, and quantitative estimates of both anaerobic and aerobic energy supply via GPDH and SDH activities, respectively, and energy demand via qATPase activity.
A minimum of 100 ®bers of a given type were analyzed and averaged for calculation of ®ber type speci®c values for each animal. These averaged values were used as the dependent measures for each variable. Determination of the eect of TRT on average muscle ®ber cross-sectional area (CSA) was assessed using a two-way (muscle6group) analysis of variance (ANO-VA). Group dierences in ®ber type speci®c CSA and in SDH, GPDH and qATPase activities were examined using a three-way (muscle6group6®ber type) repeated measures ANOVA. Dierences were considered signi®cant at P50.05.
Results

Muscle characteristics in control rats
The CSA of individual ®bers followed an overall hierarchy with type IIx4IIa4I (P50.01). Additionally, type IIx ®bers accounted for a greater per cent of the ®bers in the muscles studied than type IIa or type I ®bers (P50.01). Accordingly, calculation results for the relative area of these muscles occupied by a given ®ber type followed the same hierarchy as FT%. With respect to individual muscles, the hierarchy for the SOL in both FT% and relative area diered from the group data, with type I4IIa4IIx. The other muscles all resembled the group data with type IIx ®bers occupying more of the muscle than either type I or type IIa (P50.01).
The SDH, GPDH and qATPase activities of individual ®bers also followed hierarchies. The GPDH and qATPase activities followed the same hierarchy as did CSA with type IIx4IIa4I (P50.01), while the SDH activities of type I and IIa ®bers were signi®cantly higher than type IIx ®bers (P50.01). Muscle eects for SDH followed a hierarchy with SOL4GA4VL=TRI4TA (P40.01), expectedly almost opposite of that for GPDH and qATPase with TA, TRI and VL4GA4SOL (P50.02).
Eects of SCI on rat muscle
Aected muscle ®bers in SCI animals were approximately 49% smaller (P50.01, Figure 1 ) than those in control animals. A muscle6®ber type interaction indicated that ®bers in the SOL showing the greatest and those in the TA the least atrophy (P50.01). Fibers in the TRI, in contrast, were 31+2% bigger than in CON animals.
The percentage of type I ®bers was lower in the SCI compared to the CON animals (P50.01) and these ®bers occupied a smaller relative area of the aected muscle (P50.01). Muscle6®ber type6group interaction showed that transition to a faster muscle was signi®cant only for the SOL. This re¯ected the inherently low percentage of slow ®bers in the other muscles.
Average ®ber SDH activity was lower in hind-limb muscles while average ®ber GPDH and qATPase activities were higher in the SOL of SCI aected animals (P50.01). There were no dierences in the activities of these enzymes in the TRI of CON and SCI animals. Fiber type speci®c results indicate the greatest reduction in SDH activity resulting from SCI in the ®ber type with the highest initial activity, the type IIa ®bers (P50.01). There was not signi®cant group6®ber type interaction with respect to GPDH or qATPase activity (P50.17).
Eects of testosterone replacement therapy
Plasma testosterone concentrations were 3.83+1.11 ng/ ml in the sham surgery rats, 1.34+0.31 in the SCI rats without TRT and 5.67+00.83 in SCI rats with testosterone capsules. Plasma testosterone levels were higher in the SCI rats receiving testosterone than in those that did not (P50.01), but they were not signi®cantly dierent from those in sham rats. With respect to the health of the animals, there was an initial loss of body weight after SCI, but the rats continued to gain weight over the 11 weeks without becoming obese. There were no other side eects of the treatment in this group of rats, although we have noticed prostate enlargement in other groups of testosterone treated rats. The eect of TRT on average ®ber CSA in the hindlimb was an attenuation of the atrophic response resulting from SCI. Average ®ber CSA in the TRT SCI animals was higher and lower compared to SCI and CON animals, respectively (P50.01, Figure 1 ). This attenuation in ®ber atrophy was demonstrated across all ®ber types (P=0.002), and in all muscles except the TA (P50.01). The most dramatic eect was observed in the SOL, with ®bers in the TRT SCI animals being 58% larger than in SCI animals ( Figure  1) . Additionally, TRT SCI animals retained 152% more slow ®bers in the SOL than SCI animals (P50.01, Figure 2 ). There was no additional increase in size resulting from TRT in the TRI, compared to SCI alone (Figure 1) .
TRT attenuated the overall decrease in SDH activity relative to SCI animals. This resulted in a hierarchy with CON4TRT SCI4SCI (P50.01, Figure 3 ). The SCI animals also had higher values for overall GPDH and qATPase activities than CON and TRT SCI animals, thus SCI4TRT SCI=CON (P=0.02).
Discussion
The results of this study reveal new and important ®ndings with respect to TRT after SCI. Additionally, many of the ®ndings in the present work examining normal as well as SCI aected muscles are consistent with previous literature and lend validity of this work. First, the hierarchies in ®ber size and ®ber type percentage agree with existing literature. 16 Likewise, the reduction in ®ber size, SDH activity and percentage of type I ®bers as well as the increase in GPDH activity resulting from SCI are within the range of reported values for animals of similar age and duration of injury. 16, 17, 18 The most important ®nding of this study was that TRT ameliorated the decrease in ®ber CSA resulting from SCI. TRT also attenuated the slow to fast ®ber type shift as well as the decrease in oxidative enzyme activity. To our knowledge, this is the ®rst study to investigate the potential of TRT to prevent atrophy in SCI. TRT in aging sarcopenia and in other diseases with muscle wasting (for example, AIDS) results in favorable eects on bone, muscle size and strength in both low-average and hypogonadal men. 19 Increases in muscle CSA were equal, if not greater in TRT only groups than in exercise groups without TRT. 20 These data and ours for SCI both demonstrate a positive eect of TRT on muscle size without traditional overload.
The mechanisms responsible for the increased muscle size resulting from TRT remain unclear. In addition, the positive responses to TRT after SCI demonstrated in this study most likely resulted from preservation of existing muscle proteins and not the hypertrophic responses thought to occur in other androgen treated populations. Nonetheless, whether the positive responses to TRT stem from a testosterone de®ciency, a tissue-speci®c or relative resistance to androgen replacement in these populations, or some other systemic response, TRT has been shown to have bene®cial eects in populations with below average testosterone levels. This is promising for patients with SCI who show an inverse correlation between duration of injury and testosterone levels. 21 Although the data in the present work are promising, TRT did not completely ameliorate the atrophic response associated with this type of injury. Thus, additional treatment interventions aimed at further attenuating loss and/or producing skeletal muscle hypertrophy in this population may be needed. Previous studies using electrically assisted cycling or walking in long term SCI populations report minimal muscle growth. However, data generated using electrical stimulation protocols designed to mimic resistance training in short term patients have been extremely successful. 22 These results, when combined, bear similarity to training protocols in healthy populations comparing traditional resistance and endurance training: hypertrophy an obvious response to the former and not the latter. Thus, the plasticity in muscle size is seemingly aected by much the same stimuli in able-bodied and SCI aected muscle, at least in the ®rst year after injury.
Another interesting ®nding of this work was hypertrophy of the TRI after SCI. It seems reasonable that this muscle was`overloaded' after injury as the animals`ambulated' about their cage. This growth occurred in spite of the compromised androgen status of these animals. Thus local factors appeared sucient to evoke hypertrophy in unaected skeletal muscle, but this was not augmented by TRT. Whether such growth could be evoked by resistive overload of aected skeletal muscle after SCI is not clear. The hypertrophy we found with resistive loading was in patients about one year after injury, and thus likely not testosterone de®cient. 22 It is also not clear if a combination of TRT and resistive overload would be additive in long term patients who would likely be androgen de®cient. The inability of TRT to augment the 30% increase in size of unaected, apparently overloaded skeletal muscle after SCI may not be the same as increasing the size of extremely atrophied, aected skeletal muscle after injury.
The results of this paper indicate several potential bene®ts of TRT in patients with SCI, namely attenuation of transformation of aected skeletal muscle to smaller, faster and probably more fatigueable contractile machinery. These bene®ts include the potential for increased venous return, increased insulin sensitivity, and increased metabolic rate, all resulting from the maintenance of skeletal muscle characteristics after SCI. Although a myriad of health related problems occur as a result of SCI, the potential to reduce the severity of these with TRT is an exciting possibility; one that demands future research in these patients and others suering from chronic disease and/ or disability. Because TRT may impose additional health risks, responses to intermittent therapy could be speci®cally addressed.
